Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Fortress Biotech (FBIO) EBT Margin (2016 - 2025)

Historic EBT Margin for Fortress Biotech (FBIO) over the last 12 years, with Q3 2025 value amounting to 50.21%.

  • Fortress Biotech's EBT Margin rose 2322100.0% to 50.21% in Q3 2025 from the same period last year, while for Sep 2025 it was 120.06%, marking a year-over-year increase of 690800.0%. This contributed to the annual value of 209.0% for FY2024, which is 272200.0% down from last year.
  • Fortress Biotech's EBT Margin amounted to 50.21% in Q3 2025, which was up 2322100.0% from 218.43% recorded in Q2 2025.
  • In the past 5 years, Fortress Biotech's EBT Margin registered a high of 50.21% during Q3 2025, and its lowest value of 465.29% during Q1 2023.
  • Over the past 5 years, Fortress Biotech's median EBT Margin value was 238.04% (recorded in 2021), while the average stood at 225.59%.
  • Over the last 5 years, Fortress Biotech's EBT Margin had its largest YoY gain of 2905800bps in 2023, and its largest YoY loss of -2683100bps in 2023.
  • Over the past 5 years, Fortress Biotech's EBT Margin (Quarter) stood at 338.46% in 2021, then decreased by -3bps to 347.45% in 2022, then surged by 59bps to 143.41% in 2023, then decreased by -20bps to 171.82% in 2024, then soared by 129bps to 50.21% in 2025.
  • Its EBT Margin was 50.21% in Q3 2025, compared to 218.43% in Q2 2025 and 166.12% in Q1 2025.